BRW vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BRW exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid financial fundamentals, though the absence of an Altman Z-Score limits distress risk assessment. The stock appears deeply undervalued with a current price of $6.88 versus a Graham Number of $15.63 and an intrinsic value estimate of $38.35, suggesting significant margin of safety. However, weak technical trend (0/100), declining revenue (YoY -33.10%), and poor liquidity (Quick Ratio: 0.03) offset value appeal. High dividend yield (14.78%) is notable but raises sustainability concerns given the 77.92% payout ratio and negative operating margin.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BRW vs JPM: Head-to-Head Comparison
This page compares Saba Capital Income & Opportunities Fund (BRW) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.